CTP Applications Show Therapeutic Promise Across Multiple Chronic Wound Types
Summary: A retrospective real-world analysis published in Wounds (August 2025) by Carpenter et al. evaluated 446 Medicare-insured chronic wounds—including diabetic foot ulcers, venous leg ulcers, surgical, trauma, and other nonhealing wounds—treated with cellular and/or tissue-based products (CTPs) alongside standard care in non-hospital outpatient, nursing home, and home settings.
Key Findings:
- All wound types demonstrated significant reductions in mean wound area (P < .001), with large effect sizes—e.g., surgical wounds reduced from ~10.2 cm² to ~1.96 cm² (Cohen d ≈ 1.38); trauma wounds from ~7.2 cm² to ~0.88 cm² (Cohen d ≈ 0.96).
- Approximately 51% of wounds fully healed within up to 10 CTP applications; healing rates were highest in trauma (≈ 63%) and surgical wounds (≈ 44%), compared to DFU (≈ 41%) and VLU (≈ 32%).
- The average number of applications among healed wounds ranged from ~4.4 (trauma) to ~6.1 (DFUs).
- The findings align closely with prior data on DFUs and VLUs, suggesting that CTPs may serve as a broadly effective adjunct in chronic wound care across etiologies.
Read the full research in Wounds
Keywords:
cellular and/or tissue-based products (CTPs),
chronic wounds,
wound area reduction,
real-world evidence,
diabetic foot ulcer,
venous leg ulcer,
surgical wounds,
trauma wounds